Atopic dermatitis results in intrinsic barrier and immune abnormalities: Implications for contact dermatitis - 30/01/13
Corresponding author: Emma Guttman-Yassky, MD, PhD, Department of Dermatology, Mount Sinai School of Medicine, 5 E 98th St, New York, NY 10029.Abstract |
Atopic dermatitis (AD), as well as irritant contact dermatitis (ICD) and allergic contact dermatitis (ACD), are common skin diseases. These diseases are characterized by skin inflammation mediated by activated innate immunity or acquired immune mechanisms. Although AD, ICD, and ACD can be encountered in pure forms by allergists and dermatologists, patients with AD often present with increased frequency of ICD and ACD. Although a disturbed barrier alone could potentiate immune reactivity in patients with AD through increased antigen penetration, additional immune mechanisms might explain the increased susceptibility of atopic patients to ICD and ACD. This review discusses cellular pathways associated with increased skin inflammation in all 3 conditions and presents mechanisms that might contribute to the increased rate of ICD and ACD in patients with AD.
Le texte complet de cet article est disponible en PDF.Key words : Atopic dermatitis, allergic contact dermatitis, contact hypersensitivity, irritant contact dermatitis, epidermal barrier, immune activation, TH2, TH17
Abbreviations used : ACD, AD, CE, DC, dDC, DNCB, FLG, ICAM-1, ICD, LC, LN, SC, SLS, TEWL, TNCB, TSLP
Plan
| J.G.K. was supported in part by grant no. 5UL1RR024143-02 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and the NIH Roadmap for Medical Research. E.G.-Y. was supported by the Dermatology Foundation Physician Scientist Career Development Award. |
|
| Disclosure of potential conflict of interest: J. G. Krueger has received consultancy fees from Centercore, Eli Lilly, and Pfizer and has received research support from Amgen, Centercore, Eli Lilly, Merck, and Pfizer. E. Guttman-Yassky has received research support from the Dermatology Foundation to Mount Sinai School of Medicine and has received consultancy fees from Regeneron, Merck, Pfizer, and Stiefel. J. K. Gittler declares that she has no relevant conflicts of interest. |
Vol 131 - N° 2
P. 300-313 - février 2013 Retour au numéro
Article précédent
- Atopic dermatitis: A practice parameter update 2012
- Lynda Schneider, Stephen Tilles, Peter Lio, Mark Boguniewicz, Lisa Beck, Jennifer LeBovidge, Natalija Novak, David Bernstein, Joann Blessing-Moore, David Khan, David Lang, Richard Nicklas, John Oppenheimer, Jay Portnoy, Christopher Randolph, Diane Schuller, Sheldon Spector, Stephen Tilles, Dana Wallace
- Primary immunodeficiencies: A rapidly evolving story
- Nima Parvaneh, Jean-Laurent Casanova, Luigi Daniele Notarangelo, Mary Ellen Conley
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?